Changes in the expression of 17-β-hydroxysteroid dehydrogenase 13 and mitofusin 2 in liver cancer tissue and a bioinformatics analysis

Ceng ChaiMing; Yan MaoLin; Shi YiHai; Guo TaiLin; Mei AiNong; Chen JianKang; Xu GuiPing; He XiaoHong

doi:10.3969/j.issn.1001-5256.2019.12.019

Volume 35 Issue 12

Dec. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(12): 2736-2740

PDF( 2278 KB)

Changes in the expression of 17-β-hydroxysteroid dehydrogenase 13 and mitofusin 2 in liver cancer tissue and a bioinformatics analysis

DOI: 10.3969/j.issn.1001-5256.2019.12.019

Department of Cadre Diagnosis and Treatment,Fujian Provincial Hospital

Research funding:

Received Date: 2019-09-16
Published Date: 2019-12-20

Abstract

Abstract

Objective To investigate the change in the expression of 17-β-hydroxysteroid dehydrogenase 13( HSD17 B13) and mitofusin2( MFN2) in hepatocellular carcinoma( HCC) tissue and its clinical significance,and to analyze target genes by bioinformatics methods.Methods Fifteen HCC patients who received surgical treatment in Fujian Provincial Hospital from September 2017 to March 2018 were enrolled. HCC and adjacent tissues were collected after surgery. Real-time PCR and Western blot were used to measure the change in the expression of HSD17 B13 and MFN2 in HCC and adjacent tissues,and the clinical significance of such change was analyzed. The single cell sequencing database,the GTEx database,and The Cancer Genome Atlas database were used to analyze the expression of HSD17 B13 and MFN2 in HCC tissue and different stages of HCC,as well as its correlation with overall survival of liver cancer. The correlation between the expression of HSD17 B13 and MFN2 was also analyzed. For normally distributed continuous data,the t test was used for comparison between two groups,and an analysis of variance was used for comparison between multiple groups; for non-normally distributed continuous data,the Mann-Whitney U test was used for comparison between two groups,and the Kruskal-Wallis H test was used for comparison between multiple groups. The log-rank test was used to investigate the influence of variables on survival rate,and the Kaplan-Meier method was used for plotting the survival curve. A Pearson correlation analysis was used to investigate the relationship between the two variables. Results Real-time PCR and Western blot showed that compared with the adjacent tissue,the HCC tissue had significantly downregulated expression of HSD17 B13 and MFN2( PCR: t =-2. 467 and-3. 933,P = 0. 020 and 0. 001; Western blot: t =-5. 357 and-5. 771,P = 0. 006 and0. 026). The bioinformatics analysis showed significantly downregulated expression of HSD17 B13 in HCC tissue( P < 0. 05),and the expression of HSD17 B13 decreased with the increase in the stage of HCC( F = 3. 220,P = 0. 023); low expression of HSD17 B13 was associated with poor survival( risk ratio = 0. 630,P = 0. 011); in HCC tissue,the expression of MFN2 was positively correlated with that of HSD17 B13( r = 0. 190,P < 0. 001). Conclusion There is downregulated expression of MFN2 and HSD17 B13 in liver cancer,and MFN2 and HSD17 B13 may be potential tumor suppressor genes with clinical relevance. They may be involved in biological behaviors in the development and progression of liver cancer and may become useful molecular markers for liver cancer screening,clinical classification,and prognosis evaluation and effective targets for the treatment of liver cancer.
- carcinoma,hepatocellular,
- progesterone reductase,
- mitochondrial membrane transport proteins,
- computational biology,
- genes,tumor suppressor

FullText(HTML)

References(19)

References

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.

[3] LEE S,ZHANG C,LIU Z,et al. Network analyses identify liver-specific targets for treating liver diseases[J]. Mol Syst Biol,2017,13(8):938.

[4] WANG X,LIAO X,YANG C,et al. Identification of prognostic biomarkers for patients with hepatocellular carcinoma after hepatectomy[J]. Oncol Rep,2019,41(3):1586-1602.

[5] LI J,KE W,ZHOU Q,et al. Tumour necrosis factor-αpromotes liver ischaemia-reperfusion injury through the PGC-1α/Mfn2 pathway[J]. J Cell Mol Med,2014,18(9):1863-1873.

[6] MANCINI G,PIRRUCCIO K,YANG X,et al. Mitofusin 2 in mature adipocytes controls adiposity and body weight[J]. Cell Rep,2019,27(2):648.

[7] HERNNDEZ-ALVAREZ MI,SEBASTIN D,VIVES S,et al.Deficient endoplasmic reticulum-mitochondrial phosphatidylserine transfer causes liver disease[J]. Cell,2019,177(4):881-895.

[8] WU Y,ZHOU D,XU X,et al. Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma[J]. World J Surg Oncol,2016,14(1):179.

[9] CAI M,XU L,SHEN L,et al. Expression of long-chain noncoding RNA FOXN3-AS2 in hepatocellular carcinoma and its effect on proliferation and invasion of hepatoma cells[J]. Chin J Clin Pharmacol Ther,2018,23(11):1246-1251.(in Chinese)蔡民，许浏，沈兰，等．长链非编码RNA FOXN3-AS2在肝癌中的表达及其对肝癌细胞增殖和侵袭的影响[J]．中国临床药理学与治疗学，2018,23(11):1246-1251.

[10] LIU JZ,HU GJ,SHI LL,et al. Notch signaling pathway involved in invasion and migration of liver cancer cells[J]. Clin J Med Offic,2017,45(11):1159-1161.(in Chinese)刘建中，胡广军，时玲玲，等．Notch信号通路参与肝癌细胞侵袭迁移临床机制研究[J]．临床军医杂志，2017,45(11):1159-1161.

[11] WANG C,GONG J,WU H. Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease[J]. Biomed Rep,2017,7(2):95-104.

[12] ADAM M,HEIKELH,SOBOLEWSKI C,et al. Hydroxysteroid(17β)dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice[J]. FASEB J,2018,32(6):3434-3447.

[13] CHEN J,ZHUO JY,YANG F,et al. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int,2018,17(3):220-226.

[14] XU G,YANG F,DING CL,et al. Small nucleolar RNA 113-1suppresses tumorigenesis in hepatocellular carcinoma[J].Mol Cancer,2014,13:216.

[15] YU CB,ZHU LY,WANG YG,et al. Systemic transcriptome analysis of hepatocellular carcinoma[J]. Tumour Biol,2016,37(10):13323-13331.

[16] SUN B,KARIN M. Obesity,inflammation,and liver cancer[J]. J Hepatol,2012,56(3):704-713.

[17] CHENG X,ZHOU D,WEI J,et al. Cell-cycle arrest at G2/M and proliferation inhibition by adenovirus-expressed mitofusin-2 gene in human colorectal cancer cell lines[J]. Neoplasma,2013,60(6):620-626.

[18] WANG W,LU J,ZHU F,et al. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells[J]. Med Oncol,2012,29(1):70-76.

[19] SONG J,ZHAO W,LU C,et al. LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK-Mfn2 signaling pathway[J]. Cancer Cell Int,2019,19:60.

Relative Articles

[1]	Meng LU, Mingjie WANG, Li CHEN. Advances in the application of elastography in noninvasive diagnosis of liver fibrosis in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(2): 408-412. doi: 10.3969/j.issn.1001-5256.2023.02.025
[2]	Zhiran YANG, Linheng WANG, Yuan LI, Fusheng LIU, Yu WANG, Jianfang WANG, Runhua CHEN. Diagnostic value of transient elastography in the staging of hepatic fibrosis in patients with autoimmune liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(1): 97-103. doi: 10.3969/j.issn.1001-5256.2022.01.015
[3]	Mingjie YAO, Xiajie WEN, Leijie WANG, Qiong HE, Jianwen LUO, Jiangao FAN, Qing XIE, Chengwei CHEN, Qing Chun FU, Jun Ping SHI, Yongfeng YANG, Yun XU, Lungen LU, Fengmin LU. Establishment of a model for evaluating the severity of nonalcoholic fatty liver disease based on transient elastography parameters[J]. Journal of Clinical Hepatology, 2021, 37(7): 1614-1618. doi: 10.3969/j.issn.1001-5256.2021.07.027
[4]	Kaimin SONG, Jun LIU. Advances in the application of transient elastography in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(2): 419-424. doi: 10.3969/j.issn.1001-5256.2021.02.036
[5]	Lin JingQi, Tian Bing, Deng BaoCheng. Application of ultrasound elastography in evaluating portal hypertension[J]. Journal of Clinical Hepatology, 2020, 36(10): 2310-2314. doi: 10.3969/j.issn.1001-5256.2020.10.033
[6]	Chen WeiTing, Li ShuangJie. Clinical value of transient elastography,aspartate aminotransferase-to-platelet ratio index,and fibrosis-4 in the diagnosis of liver fibrosis in children with biliary atresia[J]. Journal of Clinical Hepatology, 2020, 36(3): 546-550. doi: 10.3969/j.issn.1001-5256.2020.03.015
[7]	SUN YiFei, HUANG LiPing. Noninvasive evaluation of esophageal and gastric varices in liver cirrhosis by shear-wave ultrasound elastography[J]. Journal of Clinical Hepatology, 2020, 36(12): 2815-2818. doi: 10.3969/j.issn.1001-5256.2020.12.036
[8]	Zhang DaKun, Chen Min, Zhang WenHui, Wang RuiFang, Shi XiaoJuan. Clinical value of acoustic radiation force impulse elastography in predicting esophageal variceal bleeding in liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(3): 561-564. doi: 10.3969/j.issn.1001-5256.2020.03.018
[9]	Liu LinXiang, Nie Yuan, Zhu Xuan. Clinical application of transient elastography in liver cirrhosis and its complications[J]. Journal of Clinical Hepatology, 2020, 36(6): 1362-1365. doi: 10.3969/j.issn.1001-5256.2020.06.037
[10]	Luo WenPing, Ma Hong, Wang Yu. Advances in the application of transient elastography in noninvasive diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(3): 635-639. doi: 10.3969/j.issn.1001-5256.2019.03.041
[11]	Chen Min, Zhang DaKun, Gao YueJuan, Li Meng, Wang RuiFang, Zhang WenHui. Clinical value of acoustic radiation force impulse in quantitative prediction of the degree of esophageal varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 80-83. doi: 10.3969/j.issn.1001-5256.2018.01.016
[12]	Xu FengMing, Sheng QingShou. Research advances in serum markers and transient elastography in the evaluation of liver fibrosis[J]. Journal of Clinical Hepatology, 2018, 34(3): 618-622. doi: 10.3969/j.issn.1001-5256.2018.03.040
[13]	Dong Xue, Huang LiPing. Research advances in the value of ultrasound elastography in the diagnosis of gastroesophageal varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2424-2427. doi: 10.3969/j.issn.1001-5256.2018.11.035
[14]	Wu Yue, Huang LiPing. Value of real-time shear wave elastography in evaluating classification of liver fibrosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(9): 1717-1721. doi: 10.3969/j.issn.1001-5256.2017.09.017
[15]	Zhuang XiaoFang, Sun Jie, Wang XiaoBo, Wang Yan, Wu QiQi, Wang XiaoZhong. Performance of transient elastography in diagnosis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2366-2371. doi: 10.3969/j.issn.1001-5256.2017.12.022
[16]	Zhang XiaoTong, Guo LiPing. Value of ultrasonic elastography in diagnosis of liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(11): 2210-2213. doi: 10.3969/j.issn.1001-5256.2016.11.048
[17]	Yang MingLei, Yao DingKang. Application of magnetic resonance elastography as a non-invasive technique for diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(3): 588-592. doi: 10.3969/j.issn.1001-5256.2016.03.042
[18]	Zhou JiaLing, Wei Wei, You Hong. Progress in clinical studies of noninvasive early diagnosis of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 604-607. doi: 10.3969/j.issn.1001-5256.2014.07.007
[19]	Zhang GuoSheng, Wang TianYi, Xu YouQing, Zhou Li, Geng Nan, Chen Yu. Diagnostic value of real-time tissue elastography for liver fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 616-619. doi: 10.3969/j.issn.1001-5256.2014.07.010
[20]	Mai Jing, Gao YueQiu. The application of magnetic resonace elastography in the non-invasive diagnosis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 318-320+324.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	朱成诚，丁世兰. 超声剪切波弹性成像对肝纤维化的临床应用进展. 现代医药卫生. 2022(22): 3874-3879+3883 .
2.	肖毅，秦建伟. 肝硬化患者门静脉压力、脾静脉血流参数与SWE结果的特征分析. 甘肃科技. 2020(12): 101-104 .
3.	董丙田，黄枢. 超声弹性成像在肝脏疾病的临床应用. 医学综述. 2019(05): 1002-1006 .
4.	刘旭. 门静脉右支前间隙行磁共振改良测量对肝纤维化和肝硬化的诊断效果. 肝脏. 2019(05): 541-544 .
5.	杨淑丽，诸绍锋，张蕾，石鹏，王姜莹，傅佳. 超声实时组织弹性成像定量分析对肝脏纤维化程度的诊断和鉴别诊断价值. 中国临床保健杂志. 2019(04): 526-529 .
6.	林培艺. 无创性肝纤维化检测对肝硬化严重程度的评估作用. 慢性病学杂志. 2019(07): 1109-1110+1113 .
7.	秦敏. 术前瞬时弹性超声检查对肝内结石肝切除术安全性的影响. 肝脏. 2019(08): 935-938 .
8.	许琴，贡雪灏，郭国强. 实时剪切波弹性成像对慢性乙型肝炎患者早期肝纤维化的诊断价值. 临床和实验医学杂志. 2019(20): 2225-2227 .
9.	孟艳，隆仙琴，李杰，丁文波. RTE与VTI对肝脏局灶良恶性病变的诊断. 中国临床研究. 2018(02): 255-258 .
10.	杨皖东，肖春华，陈晓，普慧敏. 弹性成像技术对肝移植供体评估的研究进展. 中国当代医药. 2018(03): 18-20 .
11.	徐列明. 中医药抗肝纤维化疗效评价的探索. 临床肝胆病杂志. 2017(05): 825-828 . 本站查看
12.	梁健，钟碧莹，汤茵，肖秀金，叶红. 肝纤维化检测在非酒精性脂肪肝诊断中的应用研究. 中国卫生标准管理. 2017(17): 110-113 .

Other cited types(6)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1316) PDF downloads(223)

Changes in the expression of 17-β-hydroxysteroid dehydrogenase 13 and mitofusin 2 in liver cancer tissue and a bioinformatics analysis

DOI: 10.3969/j.issn.1001-5256.2019.12.019